Company / News & Insights / First Wave BioPharma Announces AAPS 2022 PharmSci 360 Accepts Adrulipase Formulation Abstract

First Wave BioPharma Announces AAPS 2022 PharmSci 360 Accepts Adrulipase Formulation Abstract

Research involves microgranule delivery formulations for adrulipase

BOCA RATON, Fla., Aug. 31, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that an abstract titled, “Formulation Development of Enterically Protected Spray Dried Dispersions of Adrulipase,” has been accepted at AAPS 2022 PharmSci 360. The conference will be held Oct. 16-19 at the Boston Convention & Exhibit Center.

The abstract will detail research involving multiple spray dried dispersion (microgranule) delivery formulations of adrulipase, an experimental treatment for exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP). First Wave BioPharma, and its drug delivery formulation partner, Pace® Life Sciences, have been developing a technology for adrulipase that provides an optimal, delayed-release profile that enables significantly increased drug loading of adrulipase capsules designed to deliver active lipase within the targeted areas of the gastrointestinal (GI) tract.

Read the full press release here.